Steven Sterious
Temple University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Steven Sterious.
BJUI | 2014
Jay Simhan; Marc C. Smaldone; Brian L. Egleston; Daniel J. Canter; Steven Sterious; Anthony Corcoran; Serge Ginzburg; Robert G. Uzzo; Alexander Kutikov
To compare overall and cancer‐specific outcomes between patients with upper tract urothelial carcinoma (UTUC) managed with either radical nephroureterectomy (RNU) or nephron‐sparing measures (NSM) using a large population‐based dataset.
British Journal of Pharmacology | 2005
Ellen A. Walker; Steven Sterious
1 The purpose of the present study is to compare the capacity of opioid antagonists to elicit withdrawal jumping in mice following two acute pretreatment doses of the opioid agonist morphine. Antagonists that precipitate vigorous withdrawal jumping across both morphine treatment doses are hypothesized to be strong inverse agonists at the μ‐opioid receptor, whereas antagonists that elicit withdrawal jumping in mice treated with the high but not the low dose of morphine are hypothesized to be weak inverse agonists. 2 Male, Swiss‐Webster mice (15–30 g) were acutely treated with 56 or 180 mg kg−1 morphine 4 h prior to injection with naloxone, naltrexone, diprenorphine, nalorphine, or naloxonazine. Vertical jumping, paw tremors, and weight loss were recorded. Naloxone, naltrexone, and diprenorphine produced withdrawal jumping after 56 and 180 mg kg−1morphine pretreatment. Nalorphine and naloxonazine produced moderate withdrawal jumping after 180 mg kg−1 morphine pretreatment, but failed to elicit significant withdrawal jumping after 56 mg kg−1 morphine pretreatment. Nalorphine and naloxonazine blocked the withdrawal jumping produced by naloxone. All antagonists produced paw tremors and weight loss although these effects were generally not dose‐dependent. 3 Taken together, these findings reveal a rank order of negative intrinsic efficacy for these opioid antagonists as follows: naloxone=naltrexonediprenorphine>nalorphine=naloxonazine. Furthermore, the observation that nalorphine and naloxonazine blocked the naloxone‐induced withdrawal jumping provides additional evidence that nalorphine and naloxonazine are weaker inverse agonists than naloxone.
The Journal of Urology | 2013
Jay Simhan; Daniel J. Canter; Steven Sterious; Marc C. Smaldone; Kevin Tsai; Tianyu Li; Rosalia Viterbo; David Y.T. Chen; Richard E. Greenberg; Alexander Kutikov; Robert G. Uzzo
PURPOSE Patients with unilateral synchronous multifocal renal masses represent a unique population with renal cell carcinoma. While pathological concordance rates have been studied for bilateral cases, limited data exist on unilateral multifocal disease. We characterized pathological concordance rates in this population and evaluated the outcomes of nephron preservation. MATERIALS AND METHODS Patients who underwent surgery from 2000 to 2012 for unilateral synchronous multifocal renal masses were identified from a prospectively maintained database. Demographic, surgical and pathological outcomes of this cohort were analyzed. Malignant concordance rates were defined as agreement of all malignant tumor types in a single renal unit. Histological concordance was defined as agreement of all resected mass histologies, eg all clear cell carcinomas. Nuclear grade was considered concordant if all tumors excised were low (Fuhrman 1 or 2, type 1) or high (Fuhrman 3 or 4, type 2) grade. RESULTS Using our institutional database of 2,569 patients with renal tumors we identified 97 with unilateral synchronous multifocal renal masses. Malignant and benign concordance rates were 77.2% and 48.6%, and histological and grade concordance rates were 58.8% and 51.5%, respectively. In this cohort we identified 76 patients (76.3% male) with a median age of 62.5 years who had a total of 241 unilateral synchronous multifocal renal masses and underwent nephron sparing surgery. Median mass size was 2.0 cm (IQR 1.1-3.1), there was a median of 3 tumors per patient and median followup was 24 months (IQR 13-40). Identified renal cell carcinoma histologies included clear cell in 49.4% of cases, papillary in 33.5%, mixed in 4.5% and chromophobe in 2.8%. CONCLUSIONS In what is to our knowledge the largest published report of unilateral synchronous multifocal renal masses we document low pathological concordance rates. As such, percutaneous biopsy of a single renal mass in these patients may not help inform treatment decisions. Nephron sparing surgery may be performed with acceptable oncological and functional results in patients with unilateral synchronous multifocal renal masses.
European Journal of Pharmacology | 2004
Robert B. Raffa; Ellen A. Walker; Steven Sterious
Journal of Pharmacology and Experimental Therapeutics | 2003
Steven Sterious; Ellen A. Walker
The Journal of Urology | 2018
Jacob Lucas; Matthew Brennan; Brett Styskel; Ronak Gor; Tianyu Li; Steven Sterious; Robert G. Uzzo; Jay Simhan
The Journal of Urology | 2015
Ronak Gor; Robert G. Uzzo; Tianyu Li; Timothy Ito; Philip Abbosh; Daniel Canter; Justin Friedlander; Jay Simhan; Steven Sterious; David Chen; Rosalia Viterbo; Richard E. Greenberg; Marc C. Smaldone; Alexander Kutikov; Serge Ginzburg
The Journal of Urology | 2013
Jay Simhan; Marc C. Smaldone; Kevin Tsai; Tianyu Li; Daniel Canter; Anthony Corcoran; Serge Ginzburg; Steven Sterious; Zachary Piotrowski; Rosalia Viterbo; David Chen; Richard E. Greenberg; Alexander Kutikov; Robert G. Uzzo
The Journal of Urology | 2012
Steven Sterious; Jay Simhan; Jose Reyes; Marc C. Smaldone; Tianyu Li; Edward Wameedh; Tahseen Al-Saleem; Alexander Kutikov; David Chen; Rosalia Viterbo; Richard E. Greenberg; Robert G. Uzzo
The Journal of Urology | 2012
Steven Sterious; Ryan N. Fogg; Boris Gershman; Jay Simhan; Jose Reyes; Christopher J. Long; Tianyu Li; Karthik Devarajan; Sylwester Ratowt; Ervin Teper; Marc C. Smaldone; Serge Ginzberg; Anthony Corcoran; Robert G. Uzzo; Alexander Kutikov